These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 19324483)

  • 1. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
    Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
    Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of vascular access type among incident hemodialysis patients: description and association with mortality.
    Bradbury BD; Chen F; Furniss A; Pisoni RL; Keen M; Mapes D; Krishnan M
    Am J Kidney Dis; 2009 May; 53(5):804-14. PubMed ID: 19268411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
    Bradbury BD; Wang O; Critchlow CW; Rothman KJ; Heagerty P; Keen M; Acquavella JF
    Am J Kidney Dis; 2008 Jan; 51(1):62-70. PubMed ID: 18155534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbid conditions and gender impact the primary survival of distal radio-cephalic arteriovenous fistula inpatients on long-term hemodialysis.
    Vernaglione L; Mele G; Cristofano C; Distratis C; Perrone F; Frascina M; Pennacchiotti F; Chimienti S
    J Nephrol; 2005; 18(3):276-81. PubMed ID: 16013015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial.
    Santoro A; Mancini E; Bolzani R; Boggi R; Cagnoli L; Francioso A; Fusaroli M; Piazza V; Rapanà R; Strippoli GF
    Am J Kidney Dis; 2008 Sep; 52(3):507-18. PubMed ID: 18617304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes.
    Lee T; Barker J; Allon M
    Am J Kidney Dis; 2005 Sep; 46(3):501-8. PubMed ID: 16129212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access thrombosis, hospitalization, and hematocrit level in hemodialysis patients.
    Heard KA; Russell TA
    Nephrol Nurs J; 2000 Dec; 27(6):607-11. PubMed ID: 16649341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular access for hemodialysis: the impact on morbidity and mortality.
    Di Iorio BR; Bellizzi V; Cillo N; Cirillo M; Avella F; Andreucci VE; De Santo NG
    J Nephrol; 2004; 17(1):19-25. PubMed ID: 15151255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fistulae or catheter for elderly who start hemodialysis without permanent vascular access?].
    García Cortés MJ; Viedma G; Sánchez Perales MC; Borrego FJ; Borrego J; Pérez del Barrio P; Gil Cunquero JM; Liébana A; Pérez Bañasco V
    Nefrologia; 2005; 25(3):307-14. PubMed ID: 16053012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
    Lacson E; Wang W; Hakim RM; Teng M; Lazarus JM
    Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy.
    Park J; Gage BF; Vijayan A
    Am J Kidney Dis; 2005 Nov; 46(5):791-8. PubMed ID: 16253718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of vascular access type on outcome measures in patients on maintenance hemodialysis.
    Chand DH; Teo BW; Fatica RA; Brier M;
    Nephron Clin Pract; 2008; 108(2):c91-8. PubMed ID: 18212514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Saran R; Dykstra DM; Wolfe RA; Gillespie B; Held PJ; Young EW;
    Am J Kidney Dis; 2002 Dec; 40(6):1255-63. PubMed ID: 12460045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
    J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.